
With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.
Crizanlizumab is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands.
Medication Pearl of the Day: Crizanlizumab (Adakveo)
Crizanlizumab is a selectin blocker indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients 16 years of age and older with sickle cell disease.
Explanations:
Sources:





